Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®Phase 3 trial of ...
Objective Insomnia often co-exists with hip or knee pain and is associated with greater pain severity. However, there is ...
Assessments occurred at baseline (T1), 8 weeks after treatment (T2), and at a 6-month follow-up (T3) via web-based self-assessment and diagnostic telephone interviews. The primary outcome was insomnia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback